Condensed Consolidated Statements of Cash Flows (USD $)	3 Months Ended
	Jun. 29, 2012	Jul. 01, 2011
Cash flows from operating activities:
Net income (loss)	$ (993,000)	$ 18,000
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation	200,000	257,000
Amortization	292,000	342,000
Stock based compensation expense	29,000	36,000
Change in fair value of warrant liability	(17,000)	(492,000)
Changes in operating assets and liabilities:
Accounts receivable - net	196,000	(227,000)
Inventories	267,000	(287,000)
Prepaid expenses and other assets	(71,000)	33,000
Accounts payable and accrued expenses	39,000	(257,000)
Net cash used in operating activities	(58,000)	(577,000)
Cash flows from investing activities:
Capital expenditures	(95,000)	(368,000)
Patent expenditures	(10,000)	(64,000)
Net cash used in investing activities	(105,000)	(432,000)
Cash flows from financing activities:
Proceeds on bank line of credit	800,000
Payments on bank line of credit	(500,000)
Payments on bank term loan	(84,000)	(145,000)
Payments on MEDC/MSF term loan	(130,000)	(169,000)
Payments on related parties debt		(75,000)
Proceeds from exercise of stock options		9,000
Net cash provided by (used in) financing activities	86,000	(380,000)
Net decrease in cash and cash equivalents	(77,000)	(1,389,000)
Cash and cash equivalents at beginning of period	3,249,000	4,744,000
Cash and cash equivalents at end of period	3,172,000	3,355,000
Supplemental disclosure of cash flow information:
Cash paid for interest	$ 31,000	$ 62,000